Potential real-world benefits of low-dose rivaroxaban in Chinese stable cardiovascular patients

Back

ESC Premium Access

Potential real-world benefits of low-dose rivaroxaban in Chinese stable cardiovascular patients

Session: Perspectives on anticoagulation across cardiovascular disease

Topic: Anticoagulants

Speaker: Professor B. Yan (Hong Kong, CN)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Bryan Ping Yen Yan

The Chinese University of Hong Kong, Hong Kong (China)

0 follower

7 more presentations in this session

Use of Non-vitamin K antagonist Oral Anticoagulants in a real-world setting: a community pharmacy-based study.

Speaker: Mr A. Capiau (Ghent, BE)

Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: a prospective cohort study.

Speaker: Doctor M. Vedovati (Perugia, IT)

Risk of arterial calcification by conventional vitamin K antagonist treatment

Speaker: Doctor S. Hasific (Odense, DK)

Efficacy and safety of uninterrupted periprocedural edoxaban in patients undergoing catheter ablation for atrial fibrillation: Prospective KYU-RABLE study

Speaker: Professor N. Takahashi (Oita, JP)

Real world persistence with direct oral anticoagulants in anticoagulation naive patients with atrial fibrillation

Speaker: Doctor G. Denas (Padova, IT)

Access the full session

Perspectives on anticoagulation across cardiovascular disease

Speakers: Professor B. Yan, Mr A. Capiau, Doctor M. Vedovati, Doctor S. Hasific, Professor N. Takahashi...

Access

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources